Garen G. Bohlin
Independent DirectorMr. Garen G. Bohlin has been an Independent Director of Mr. Bohlin joined the Collegium Pharmaceutical, Inc. in January 2015. Pharmaceutical, Inc. since January 2015. He had been an Independent Director at Tetraphase Pharmaceuticals, Inc. since July 2010 until July 28, 2020. Mr. Bohlin also serves as Chairman of Curadel Surgical Innovations, Inc. Mr. Bohlin served as an Executive Vice President of Constellation Pharmaceuticals, Inc. from January 2010 to April 2012, where he served as a part-time business Partner with the Chief Executive Officer. He was responsible for Constellation’s corporate operations and finance function. He served Senior Executive posts in leading biotechnology companies. He served as Principal Financial Officer and Assistant Secretary of Sirtris Pharmaceuticals, Inc. and also served as its Chief Operating Officer from January 2006 to December 2009. He played key roles in the overall management of Sirtris, its initial public offering and the sale of it to GlaxoSmithKline. He served as the Founding President and Founding Chief Executive Officer of Syntonix Pharmaceuticals Inc from 1999 to December 2005, where he positioned it for its sale to Biogen Idec. where he played a key role in the overall management of Syntonix, positioning it for an eventual sale to Biogen Idec. He joined Syntonix in 1998. He worked at Genetics Institute, LLC where he served as Chief Financial Officer and Executive Vice President since January 1990 and also served as it Principal Accounting Officer with responsibility for most of the non-scientific areas of Genetics that comprised approximately half of its then 1,600 employees. He joined Genetics Institute LLC in December 1983 as Director of Finance & Treasurer and served as its Vice President of Finance and Senior Vice President of Finance & Administration. He served as an Executive at Wyeth. He played an integral role in structuring the sale of Genetics Institute, LLC to American Home Products (Wyeth). He worked at Arthur Andersen & Co. where he was a Partner and oversaw all client activities for a broad range of Fortune 500 businesses, as well as smaller publicly and privately owned companies. He has also held various operating roles in the life sciences field. He played a leading role in structuring and implementing a strategic alliance with Wyeth. He served as Chairman of SpringLeaf Therapeutics, Inc. Mr. Bohlin has been an Independent Director of Karyopharm Therapeutics Inc. since October 3, 2013. He previously served as a Director of several private and public biotechnology companies. He has extensive industry and Board experience. He served as an Independent Director at Acusphere, Inc. from January 25, 2005 to January 2015. He served as Director of Curadel Surgical Innovations, Inc. a private biopharmaceutical company, since March 2020. He served as a Director of Praecis Pharmaceuticals Inc. from 2005 to 2007 and Protara Therapeutics, Inc. He served as an Independent Board Member of Targanta Therapeutics Corp. from May 2007 to February 25, 2009. He served as a Director of Syntonix Pharmaceuticals, Inc. since 1998, Precision Dermatology, Inc. since December 10, 2012 to July 2014 and SpringLeaf Therapeutics, Inc. from 2010 to 2013. He was the President of the Massachusetts biotechnology trade association. He is a Director of Massachusetts biotechnology trade association. He has been a Consultant to various life sciences and healthcare companies since May 2012. Since April 2012, he has focused exclusively on service on boards of Directors and consulting. He had been an Independent Director of Proteon Therapeutics Inc since September 2014 to 2020. Mr. Bohlin holds a B. S. in Accounting and Finance from the University of Illinois in 1970 and then spent over a decade at Arthur Andersen & Co. where he was a Partner.
Positions
- Company NameKaryopharm Therapeutics Inc.Stock CodeKPTIQPositionIndependent DirectorColleagues
- RARichard A. PaulsonPresident, CEO & Director
- SPStuart PoultonExecutive VP & Chief Development Officer
- RRReshma RangwalaExecutive VP, Chief Medical Officer & Head of Research
- SSSharon ShachamCo-Founder & Chairman of Scientific Advisory Board
- LALori A. MacomberEVP, CFO & Treasurer
- BEBarry E. GreeneLead Independent Director
- DRDeepika Rachel PakianathanIndependent Director
- GGGaren G. BohlinIndependent Director
- Company NameCollegium Pharmaceutical, Inc.Stock CodeCOLLPositionIndependent DirectorColleagues
- VKVikram KarnaniCEO, President & Director
- GSGino SantiniIndependent Chairman
- CTColleen TupperExecutive VP & CFO
- DDDavid DieterExecutive VP, General Counsel & Corporate Secretary
- TBThomas B. SmithExecutive VP & Chief Medical Officer
- IKIan KarpHead of Investor Relations
- RJRita J. Balice-GordonIndependent Director
- NSNancy S. LurkerIndependent Director
